CME: Metastatic urothelial carcinoma (mUC): Updates from the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
ACCREDITATION EXPIRED: August 24, 2025
Activity Description / Statement of Need:
In this online, self-learning activity:
Urothelial carcinoma (UC) is a cancer affecting both the bladder and beyond, including tumors of the upper urinary tract and proximal urethra. Cancers of the urinary tract affect more than 1.6 million people worldwide and collectively are the 6th most common type of cancer in the US. UC itself accounts for over 82,000 new cases and over 16,000 deaths each year. The five-year survival for noninvasive UC is 96% but drops to eight percent for metastatic disease (mUC), suggesting there may be room for improvement in the management of the disease.
Target Audience:
HCPs including: medical and genitourinary oncologist and urologist; physician assistants, nurse practitioners, nurses, and pharmacists who practice in oncology and urology; and any other HCPs with an interest in or who clinically encounter patients with mUC.
Commercial Support Disclosure: This program is supported by an educational grant from Merck.
This activity is free of charge.
Release Date: August 24, 2024 -- Expiration Date: August 24, 2025
Faculty: Waddah Arafat, MD
Agenda
|
Faculty member introduction, disclosures, overview of mUC |
|
Major findings from ASCO 2024:
|
|
Patient cases |
|
Concluding remarks |
Learning Objectives
By the end of the session the participant will be able to:
- Review the practice-changing Ultima trial for the management of urachal cancer.
- Recall the patient-related outcomes (PRO) and quality-of-life (QoL) data from the EV-302 trial.
- Describe how response to EV is impacted by upfront dose intensity and later dose reductions.
- Review the response data of NivoCisGem in node-only mUC patients.
- Apply the findings presented at ASCO to patient cases.
Accreditation
ACCME Activity #202808783
ACCREDITATION FOR THIS COURSE HAS EXPIRED. YOU MAY VIEW THE PROGRAM, BUT CME / CE IS NO LONGER AVAILABLE AND NO CERTIFICATE WILL BE ISSUED.Faculty Disclosure and Resolution of COI
As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review by ScientiaCME.
Disclosures of Faculty: Waddah Arafat, MD, Assistant Professor, Genitourinary Oncology, University of Texas Southwestern Medical Center, has received financial compensation from Seagen, Astellas, Exelixis, AstraZenca, Merck for grant/research support; in addition to consulting work for Cardinal Health (relationship has ended).
Disclosures of Educational Planners: Charles Turck, PharmD, BCPS, BCCCP, President of ScientiaCME, has no relevant financial disclosures.
Faculty WILL discuss off-label uses of a commercial product.
All relevant financial relationships have been mitigated.
ScientiaCME adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Commercial Support Disclosure: This program is supported by an educational grant from Merck.
Instructions
- Read the learning objectives above
- Take the Pre-Test (optional). Completion of the pre-test will help us evaluate the knowledge gained by participating in this CME activity.
- View the online activity. You may view this is in more than one session, and may pause or repeat any portion of the presentation if you need to.
- Minimum participation threshold: Take the post-test. A score of 70% or higher is required to pass and proceed to the activity evaluation.
- Complete the activity evaluation and CME registration. A CE certificate will be emailed to you immediately.
System Requirements
Windows 7 or above
Internet Explorer 8
*Adobe Acrobat Reader
Mac OS 10.2.8
Safari or Chrome or Firefox
*Adobe Acrobat Reader
Internet Explorer is not supported on the Macintosh
*Required to view Printable PDF Version
Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.
Additional Courses That Are Related To This Activity
Advanced systemic mastocytosis: from recognition to treatment
Taking the next step in the management of relapsed or refractory follicular lymphoma
Initial- and later-line treatment considerations in advanced renal cell carcinoma (RCC)